The present invention provides: a protoporphyrin IX fluorescence enhancer comprising a nucleic acid having a G4 structure, the nucleic acid having the G4 structure being a nucleic acid that is bound to or complexed with a substance having cell membrane permeability; a method for producing a fluorine-containing G4 compound, in which an amidide derivative compound containing a fluorine-containing group and a nucleic acid having a guanine quadruplex structure are bound by a phosphoramidite method to synthesize a fluorine-containing G4 compound in which the nucleic acid having the guanine quadruplex structure and the fluorine-containing group are linked via a linking group; a medicinal composition having the fluorescence enhancer as an active ingredient; a cancer cell visualization kit containing the fluorescence enhancer and 5-aminolevulinic acid; and a cancer cell visualization method in which the fluorescence enhancer and 5-aminolevulinic acid are introduced into an in-vitro cancer cell.
KANAGAWA INSTITUTE OF INDUSTRIAL SCIENCE AND TECHNOLOGY (Japan)
INSTITUTE OF SCIENCE TOKYO (Japan)
UNIVERSITY OF MIYAZAKI (Japan)
FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE (Japan)
Inventor
Ajioka Itsuki
Muraoka Takahiro
Miyauchi Chikako
Kitamura Kazuo
Nishimura Hideo
Abstract
The present invention addresses the problem of providing a novel method for treating cerebral infarction that does not depend on cell transplantation. Provided is a fusion peptide obtained by linking adrenomedullin or an active fragment thereof with a self-assembling peptide.
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
A61L 27/54 - Biologically active materials, e.g. therapeutic substances
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
An insulating film for a secondary battery, which has desired insulating property and heat resistance, and which contributes to an increase of the energy density of a battery without considerable increase of the thickness. An insulating film for a secondary battery, including a substrate film which is a polyolefin microporous membrane, and having a metal oxide contained in the substrate film. In the insulating film, the metal oxide is contained in at least some of micropores and is present on the inner wall of the micropores. A method for producing the insulating film for a secondary battery is a method of spraying a solution containing an alkyl compound corresponding to a metal of the metal oxide and/or a partial hydrolysate of the alkyl compound over the substrate film, and drying the solution.
H01M 50/451 - Separators, membranes or diaphragms characterised by the material having a layered structure comprising layers of only organic material and layers containing inorganic material
H01M 50/489 - Separators, membranes, diaphragms or spacing elements inside the cells, characterised by their physical properties, e.g. swelling degree, hydrophilicity or shut down properties
An artificial meniscus that is a supportive device for a knee joint, which is circular in shape, and less likely to be displaced is disclosed. The artificial meniscus includes a polycarbonate urethane and has a shell having flexibility and a core having a rigidity higher than that of the shell. A surface of the artificial meniscus is coated by MPC and micro dimples are formed on a surface of the artificial meniscus. The artificial meniscus is placed between the femur and tibia and is sewn to an articular capsule.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japan)
UNIVERSITY OF MIYAZAKI (Japan)
Inventor
Chakraborty, Tapas
Ohta, Kohei
Matsuyama, Michiya
Mohapatra, Sipra
Yahiro, Issei
Mizumura, Kodai
Nagano, Naoki
Abstract
The present invention provides a method for culturing a fish germ stem cell, including culturing the stem cell on a surface coated with vitronectin and in a medium containing the following 8 components:
(1) insulin,
(2) selenium,
(3) transferrin,
(4) L-ascorbic acid,
(5) FGF2,
(6) TGFβ,
(7) NaHCO3 or KHCO3,
(8) L-glutamine.
In order to provide a suturing member that makes it possible to easily and reliably suture a defect in mucous membrane of a digestive tract wall, a suturing member 100A for use in suturing a defect in mucosal membrane of a digestive tract wall is characterized by comprising a pair of arm plate parts 120, 130 arranged so that the separation distance therebetween increases toward distal end portions 126, 136 thereof in a state where no external force is applied, a coupling plate part 110 that couples arm proximal end portions 121, 131 of the pair of arm plate parts 120, 130, and distal end claw portions 150, 160 respectively provided at the distal end portions 126, 136 of the pair of arm plate parts 120, 130 so as to face each other, wherein one arm plate part 120 of the pair of arm plate parts 120, 130 is longer than the other arm plate part 130.
NATIONAL UNIVERSITY CORPORATION TOKYO UNIVERSITY OF MARINE SCIENCE AND TECHNOLOGY (Japan)
FUKUI PREFECTURAL UNIVERSITY (Japan)
UNIVERSITY OF MIYAZAKI (Japan)
Inventor
Matsumoto Reiko
Hoshikawa Hiroki
Sakamoto Suzuka
Ikeda Hana
Satoh Shuichi
Hayashi Masahiro
Abstract
The purpose of the present invention is to provide a fish feed capable of increasing highly unsaturated fatty acid in muscle. This problem can be solved by means of a fish feed according to the present invention, the fish feed containing a plant-based raw material and a highly unsaturated fatty acid–containing microorganism.
This invention makes it possible to measure a subject's body volume without touching the subject. This invention comprises: an acquisition unit for acquiring image information indicating a three-dimensional image in which a subject lying down on a flat surface has been imaged from above; a recognition unit for recognizing, from among objects displayed in the three-dimensional image, a subject image representing the subject; and an estimation unit for using the subject image to estimate the body volume of the subject, inclusive of a lower portion of the subject that is missing in the subject image, assuming that the lower portion is in contact with the flat surface. The invention also comprises: a step for capturing a three-dimensional image of a neonate; a step in which a computer estimates the neonate's body volume from the three-dimensional image; and a step in which the computer estimates the neonate's body weight from the estimated body volume.
A determination device includes an irradiator, an extractor, an imager, and a determiner, The irradiator irradiates an object including a food or a plant with a light. The extractor extracts a predetermined fluorescence emission having a predetermined wavelength out of fluorescence emissions generated from a surface of the object irradiated with the light. The imager captures a fluorescence image indicating the predetermined fluorescence emission. The determiner determines a state of the object based on an index indicating a fluorescence intensity of the fluorescence image.
Provided is a semiconductor image sensor device in which the occurrence of leakage current due to interface states is prevented and which operates stably without a decrease in the detection sensitivity of a photodiode. On the surface side of a silicon support substrate (101), there are provided a first buried well layer (102-1) having a first impurity concentration of a second conductivity type at a first position (A) which becomes a back gate of a MOS transistor element (114), a second buried well layer (102-2) having the first impurity concentration of the second conductivity type at a second position (B) which is spaced apart from the first position (A) and does not face the back gate, a third buried well layer (103) having a second impurity concentration of a first conductivity type that is separated from the first buried well layer (102-1) by a predetermined distance in the first direction and second direction and formed close to the second buried well layer (102-2) to surround the first buried well layer (102-1) from both sides, and a fourth buried well layer (104) having a third impurity concentration of the first conductivity type that is formed at a deeper position than the first buried well layer (102-1) and in contact with the bottom surfaces of the first buried well layer (102-1) and the third buried well layer (103).
The present invention provides a means for preventing and/or treating a symptom of a viral infection in a subject affected by the viral infection without inducing any undesired serious side effect by optimizing the application method and the dose of a medicine containing AM or a derivative thereof as an active ingredient. One aspect of the present invention relates to a medicine for preventing or treating a symptom or disorder in a subject affected by a viral infection, the medicine containing adrenomedullin or a derivative thereof as an active ingredient.
NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM (Japan)
Inventor
Kitamura Kazuo
Mizuno Masashi
Kim Hongsoo
Abstract
Provided are: a novel pharmaceutical composition for peritoneal disorders or peritoneal fibrosis accompanied by peritoneal inflammation; and a novel peritoneal dialysis fluid. The present invention provides a pharmaceutical composition for peritoneal disorders accompanied by peritoneal inflammation, the composition containing, for example, a peptide compound represented by a general formula (I) (SEQ ID NO:1) as an active ingredient. (In the formula, [Mod] represents a modifying group, [Lin] represents a linking group, and [Pep] represents a peptide chain having an amino acid sequence comprising one amino acid residue or 2-15 amino acid residues. t, s, and m each independently represent 0 or 1. Xa1 represents Val etc., Xa2 represents Gln etc., Xa3 represents Phe etc., Xa4 represents Gly etc., Xa5 represents Val etc., Xa6 represents Arg etc., Xa7 represents Ser etc., and Xa8 represents Tyr etc. Bq represents -SH HS- or -S-S-.)
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
13.
ADENOCARCINOMA DETECTION METHOD, AND EXAMINATION KIT
An adenocarcinoma detection method based on a protein fragment of WFDC2 protein in a sample originating from a subject, the method comprising determining a presence of adenocarcinoma by comparing a first determination value and a threshold value set in advance, the first determination value being a value derived by dividing a first fragment quantity, which is a quantity of a protein fragment having an amino acid sequence of SEQ ID NO: 1 in the sample as determined by an ELISA method, by a reference quantity defined by a total quantity of WFDC2 protein or a creatinine concentration in the sample as determined by an ELISA method.
The invention provides novel adrenomedullin analogs that exhibit high biological stability in administering to subjects while maintaining pharmacological effects of the parent compound adrenomedullin. An aspect of the invention relates to a compound or a salt thereof, or a solvate thereof, wherein the compound is a peptide selected from the group consisting of: (a) a peptide consisting of an amino acid sequence of SEQ ID NO: 3 wherein one to three amino acid residues are substituted or deleted; (b) a peptide having a disulfide bond formed by cysteine residues at positions 4 and 9 of the peptide of (a); (c) a peptide wherein the disulfide bond of the peptide of (b) is substituted with an ethylene group; (d) a peptide wherein one to three amino acid residues of any of the peptides of (a) to (c) are deleted or added; (e) a peptide wherein any of the peptides of (a) to (d) is amidated at the C-terminus thereof; and (f) a peptide wherein any of the peptides of (a) to (d) has a glycine residue added to the C-terminus thereof. Another aspect of the invention relates to a method for producing the compound or the like, and a medicament and agent for prevention or treatment each comprising the compound or the like as an active ingredient.
In a configuration in which an image acquisition unit that acquires an image of an animal, a shape identification unit that identifies a shape of a predetermined portion of the animal from the image, an information generation unit that, on a basis of the shape of the predetermined portion, generates estimation information used for estimating a weight of the animal, and a weight estimation unit that estimates the weight on a basis of the estimation information are provided, the information generation unit is capable of generating the estimation information both in a case where a first image (an animal image GA) in which the animal is imaged from a first direction is acquired and in a case where a second image in which the animal is imaged from a second direction that is different from the first direction is acquired.
2—B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal α-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Provided is a knee-joint supporting device that does not readily prolapse. An artificial meniscus 10 is a knee-joint supporting device and has an annular shape. The artificial meniscus 10 is positioned between the femur and the tibia. The artificial meniscus 10 contains polycarbonate urethane. The artificial meniscus 10 comprises: a flexible shell 12; and a core 11 that is more rigid than the shell 12. The artificial meniscus 10 is sutured to a joint capsule. The surface 12a of the artificial meniscus 10 is coated with MPC. Microdimples 10d are formed on the surface of the artificial meniscus 10.
This determination device comprises: an irradiation unit (10) for irradiating an object (A) including a food or a plant with light; an extraction unit (20) for extracting predetermined fluorescence having a predetermined wavelength within the fluorescence emitted from the surface of the object (A) when irradiated with light; an imaging unit (30) that captures a fluorescence image expressing the predetermined fluorescence; and a determination unit (60) that determines the state of the object (A) on the basis of an index indicating the fluorescence intensity of the fluorescence image.
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
The allele detection method comprises a reaction step in which a polymerase chain reaction is carried out using a reaction solution comprising: a nucleic acid containing an allele base sequence that forms a template; primers for base sequence amplification by a polymerase chain reaction; DNA polymerase that performs primer elongation when the 1 base at the 3'-terminal of primer hybridized to the base sequence is complementary to the base at the position in the base sequence corresponding to the position of the 1 base; a probe that hybridizes to at least a portion of the base sequence that is amplified by the DNA polymerase; and a labeling substance that indicates that the probe has hybridized to the base sequence.
C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION (Japan)
OSAKA UNIVERSITY (Japan)
UNIVERSITY OF MIYAZAKI (Japan)
Inventor
Miyamoto, Yoichi
Okamoto, Toru
Saito, Akatsuki
Oka, Masahiro
Abstract
The present disclosure provides virus suppression by a nucleolus-modifying agent. One aspect of the present disclosure provides an antivirus agent effective against a corona virus, the agent having a nucleolus-modifying agent as an active ingredient. According to one embodiment, the coronavirus includes a virus selected from the group consisting of HCoV-HKU1, HCoV-OC43, SARS-CoV, MERS-CoV, and SARS-CoV-2. According to one embodiment, the nucleolus-modifying agent contains a flavopiridol compound, AT7519, P276-00, or a CDK1/2 inhibitor III.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
A61K 31/4025 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
A61K 31/453 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
22.
METHOD FOR PRODUCING LONG-ACTING ADRENOMEDULLIN DERIVATIVE
The present invention provides a method for producing, within a shorter time frame and/or at an economical cost, a long-acting adrenomedullin derivative with which it is possible to substantially suppress undesirable side effects while maintaining the pharmacological action of adrenomedullin. One embodiment of the present invention pertains to a method for producing a compound represented by formula (I) (in the formula: A is the Fc region of immunoglobulin, B is the peptide portion derived from adrenomedullin or a modified form thereof, and L is a linking group comprising peptides having arbitrary amino acid sequences) or a salt thereof, or a hydrate thereof. The method includes an expression step for abundantly expressing said compound in cells of a host mammal capable of producing the compound. Formula (I): A-L-B
KYUSHU UNIVERSITY, NAT'L UNIVERSITY CORPORATION (Japan)
UNIVERSITY OF MIYAZAKI (Japan)
KONAN GAKUEN (Japan)
NIPPON SUISAN KAISHA, LTD. (Japan)
Inventor
Sakaguchi, Keishi
Hamaguchi, Rie
Matsuda, Takanobu
Ito, Makoto
Nagano, Naoki
Hayashi, Masahiro
Okita, Yuji
Sugimoto, Shinichi
Honda, Daisuke
Abstract
A method for producing a microbial oil includes the steps of: genetically modifying a labyrinthulid by disrupting and/or silencing a gene, or by transforming another gene in addition to the disruption and/or gene silencing of the gene; culturing the labyrinthulid, such that a fatty acid composition accumulated in the labyrinthulid comprises an increased EPA content; and collecting the microbial oil having the increased EPA content from the labyrinthulid. The increased EPA content is not less than 3.3% of a total fatty acid composition.
SINGAPORE UNIVERSITY OF TECHNOLOGY AND DESIGN (Singapore)
Inventor
Yamako Go
Chosa Etsuo
Shriram, Duraisamy
Subburaj, Karupppasamy
Abstract
The present disclosure provides a meniscus implant which can reduce contact stress on an inner compartment of a knee joint and improve the reproducibility of a tibia rotary movement when there is no damage to a meniscus. This meniscus implant 1 comprises a flexible shell 2 and a core 3 having higher stiffness than the shell 2. The shell 2 is formed in an anatomical shape of a human meniscus. The core 3 is embedded in the shell 2 and has a curved shape conforming to the anatomical shape of the human meniscus. The shell 2 has, in a front end section and a rear end section, non-reinforced sections 20 in which the core 3 is not embedded.
The present invention provides a means for preventing and/or treating a symptom of a viral infection in a subject affected by the viral infection without inducing any undesired serious side effect by optimizing the application method and the dose of a medicine containing AM or a derivative thereof as an active ingredient. One aspect of the present invention relates to a medicine for preventing or treating a symptom or a disorder in a subject affected by a viral infection, the medicine containing adrenomedullin or a derivative thereof as an active ingredient.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
The present invention provides a drug having an anti-viral activity against various viruses capable of inducing viral infections. One aspect of the present invention relates to an anti-viral agent containing adrenomedullin or a derivative thereof as an active ingredient.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present invention provides a novel long-acting adrenomedullin derivative that sustains the pharmacological effects of adrenomedullin, which is the parent compound thereof, and exhibits high biological stability when administered to a subject. One embodiment of the present invention pertains to a compound represented by formula (I) [in the formula: A represents a modifying group that is serum albumin; B represents a peptide moiety derived from adrenomedullin or a modified form thereof; and L represents a divalent linking group having a carboxyl group at at least one end thereof, wherein the α-amino group at the N-end of the peptide moiety B forms an amide bond together with the terminal carboxyl group of the linking group L so that the peptide moiety B is linked to the remainder], a salt thereof or a hydrate of the same. Another embodiment of the present invention pertains to: a method for producing the aforesaid compound, etc.; and a pharmaceutical and a prophylactic or therapeutic agent each comprising the compound, etc. as an active ingredient. (I): A-L-B
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 25/00 - Drugs for disorders of the nervous system
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
An ELISA method having excellent high throughput, wherein adenocarcinoma is efficiently detected with high sensitivity and specificity. An adenocarcinoma detection method based on a protein fragment of the WFDC2 protein in a sample originating from a subject, said method comprising determining the presence of adenocarcinoma by comparing a first determination value and a threshold value set in advance, the first determination value being a value derived by dividing a first fragment quantity, which is the quantity of a protein fragment having the amino acid sequence of SEQ ID NO: 1 in the sample as determined by an ELISA method, by a reference quantity defined by the creatinine concentration or the total quantity of WFDC2 protein in the sample as determined by an ELISA method.
The present invention provides a novel adrenomedullin analog that preserves the pharmacological effects of adorenomedullin which is a parent compound, and that demonstrates high biological stability when administered to a subject. One embodiment of the present invention relates to a compound or a salt thereof, or a solvate of the compound or a salt thereof, the compound being a peptide selected from the group consisting of: (a) a peptide comprising the amino acid sequence represented by SEQ ID NO: 3, with one to three amino acid residues substituted or deleted; (b) the peptide of (a), where the cysteine residue at position 4 and the cysteine residue at position 9 form a disulfide bond; (c) the peptide of (b), where the disulfide bond is substituted with an ethylene group; (d) the peptide of any one of (a) to (c), with one to three amino acid residues deleted or added; (e) the peptide of any one of (a) to (d), where the C-terminus is amidated; and (f) the peptide of any one of (a) to (d), where a glycine residue is added to the C-terminus. Another embodiment of the present invention relates to: a method for producing the compound; and a pharmaceutical drug, a prophylactic agent or a therapeutic agent containing the compound as an active ingredient.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
A61P 1/04 - Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
31.
Production method for guanosine derivative having fluorine atom-containing functional group at position 8 and application thereof
Provided is a weight estimation device which offers a greater degree of freedom in the imaging direction that enables estimation of the weight of an animal. A weight estimation device comprising: an image acquisition unit which acquires an image of an animal; a shape identification unit which identifies the shape of a prescribed region of the animal from said image; an information generation unit which, on the basis of the shape of the prescribed region, generates estimation information for use in estimating the weight of the animal; and a weight estimation unit which estimates the weight on the basis of the estimation information, wherein the information generation unit is capable of generating the estimation information both in the case when a first image (animal image GA) is acquired by photographing an animal from a first direction (e.g., the left side of the body) and in the case when a second image is acquired by photographing the animal from a second direction (e.g., the right side of the body) different from the first direction.
NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (Japan)
UNIVERSITY OF MIYAZAKI (Japan)
Inventor
Ihara Masafumi
Saito Satoshi
Yoshimoto Takeshi
Kitamura Kazuo
Kita Toshihiro
Abstract
The present invention provides a means for treating a symptom of cerebral infarction in a cerebral infarction patient, particularly in an acute stage cerebral infarction patient, without causing undesirable side effects, by optimizing the administration and dosage of a drug that includes, as an active ingredient, adrenomedullin (AM) or a derivative thereof having adrenomedullin activity. One aspect of the present invention relates to a drug for treating a symptom of cerebral infarction in an acute stage cerebral infarction patient, said drug including, as an active ingredient, adrenomedullin or a derivative thereof having adrenomedullin activity, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of any of these.
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE (Japan)
Inventor
Kitamura, Kazuo
Fukushima, Masanori
Nishimura, Hideo
Abstract
The present invention provides a therapeutic and/or prophylactic agent for a neurodegenerative disease with abnormal protein accumulation and a method for treating and/or preventing the disease.
A61K 38/16 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 47/56 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION AT KOBE (Japan)
Inventor
Kitamura Kazuo
Nagata Sayaka
Yamasaki Motoo
Nishimura Hideo
Nishi Masanori
Abstract
The present invention provides a means for treating or preventing diseases related to the complement system. One mode of the present invention pertains to a medicine that is for treating or preventing C3 nephropathy and that contains, as an active ingredient, adrenomedullin or an adrenomedullin derivative, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof. Another mode of the present invention pertains to a medicinal composition that is for treating or preventing C3 nephropathy and that contains: adrenomedullin or an adrenomedullin derivative, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof; and at least one pharmaceutically acceptable carrier. Still another mode of the present invention pertains to a C3b degradation accelerator that contains, as an active ingredient, adrenomedullin or an adrenomedullin derivative, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/65 - Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
The present invention provides an immune checkpoint inhibiting antibody based on a new mechanism that is useful for activating antitumor immune responses. The present invention pertains to an antibody that has an immune checkpoint inhibitory action and specifically binds to the extracellular domain of human CLEC4A protein or an antigen-binding fragment of the antibody, an antitumor use of the same, and an antitumor use of the antibody or an antigen-binding fragment thereof, said use comprising employing a T cell expressed immune checkpoint molecule inhibitor together therewith.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
The cell labeling agent includes a monosaccharide derivatives with a six-membered ring structure that are metabolized to sialic acid in the sialic acid biosynthetic pathway of cells. Among the groups bonded to carbon atoms constituting a six-membered ring in the monosaccharide derivatives, at least one group that does not change, even when metabolized by the sialic acid biosynthetic pathway, includes a ring structure with a carbon-carbon double bond or triple bond.
C07H 13/12 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group —X—C (=X)—X—, or halides thereof, in which X means nitrogen, oxygen, sulfur, selenium, or tellurium, e.g. carbonic acid, carbamic acid
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
2-B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal α-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
Provided is a means for preventing or treating arrhythmia such as atrial fibrillation after catheter ablation surgery. One aspect of the present invention relates to a medicament for preventing or treating arrhythmia after catheter ablation surgery, the medicament containing, as an active agent, adrenomedullin or a derivative thereof having adrenomedullin activity. Another aspect of the present invention relates to a pharmaceutical composition for preventing or treating arrhythmia after catheter ablation surgery, the pharmaceutical composition containing adrenomedullin or a derivative thereof having adrenomedullin activity and one or more pharmaceutically acceptable carriers.
C07K 14/46 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates
There is provided a simple and minimally invasive adenocarcinoma detection method. The adenocarcinoma detection method of the present invention includes a step of detecting in vitro a presence or absence of an abnormal cleavage in a specific protein in a test subject-derived sample. The abnormal cleavage in the specific protein is, for example, a cleavage resulting in one or more breaks in a peptide bond in the specific protein and/or a cleavage resulting in a deletion of one or two more amino acid residues at one or more sites of the specific protein. The adenocarcinoma detection method of the present invention includes a step of detecting a presence or amount of a protein having the abnormal cleavage or a decrease in an amount of a normal protein.
[Problem] To develop a technique for genetic determination of shigella. [Solution] A method for determining a shigella O-serogroup characterized by comprising subjecting shigella O-antigen gene to nucleic acid amplification and thus determining the serotype of shigella. In a preferred embodiment, the nucleic acid amplification is carried out by the PCR method with the use of one or more of the primer sets represented by primer set numbers 1 to 34. Still preferably, use can be made of, from among these primer sets, primer set 10 (SEQ ID NOS: 19 and 20), primer set 15 (SEQ ID NOS: 29 and 30), primer set 20 (SEQ ID NOS: 39 and 40), primer set 22 (SEQ ID NOS: 43 and 44), primer set 25 (SEQ ID NOS: 49 and 50), primer set 26 (SEQ ID NOS: 51 and 52), primer set 30 (SEQ ID NOS: 59 and 60), primer set 31 (SEQ ID NOS: 61 and 62) and primer set 32 (SEQ ID NOS: 63 and 64).
C12Q 1/689 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
Provided is an ultrasonic vibration processing device which can suppress vibration of components due to an ultrasonic vibrator and can perform processing using ultrasonic vibration in a preferable manner; the ultrasonic vibration processing device includes: a housing (10); an ultrasonic vibrator (20) including a horn portion (21A) to which a tool holder (70) is detachably attached and a piezoelectric element (23), the ultrasonic vibrator having a rear end located at a node of ultrasonic vibration and being supported inside the housing (10) so as to be rotatable; a connecting portion (30) stored in the housing (10) so as to be rotatable together with the ultrasonic vibrator (20); a motor (40) connected to the connecting portion (30); and a non-contact power supply unit (50) including a primary transformer (51) and a secondary transformer (52), the primary transformer (51) being fixed to the housing (10) and including a primary coil (51B) that receives high frequency power from an external power supply, the secondary transformer (52) being connected to the rear end of the ultrasonic vibrator (20) with a clearance maintained between the secondary transformer (52) and the primary transformer (51) and including a secondary coil (52B) that supplies an induced electromotive force to the piezoelectric element (23).
B23B 37/00 - Boring by making use of vibrations of ultrasonic frequency
B06B 1/06 - Processes or apparatus for generating mechanical vibrations of infrasonic, sonic or ultrasonic frequency making use of electrical energy operating with piezoelectric effect or with electrostriction
Provided is a lung adenocarcinoma detection method that is simple and is less invasive. The lung adenocarcinoma detection method of the present invention includes the step of detecting the presence or absence of an abnormal cleavage in kininogen I in a sample collected from a subject in vitro. The abnormal cleavage in kininogen I is, for example, a cleavage that can form at least one cleaved site in a peptide bond in kininogen I and/or a cleavage that causes the deletion of at least one amino acid residue at least one site in kininogen I. The lung adenocarcinoma detection method according to the present invention includes the step of detecting the presence or amount of a protein having the above-mentioned abnormal cleavage or the loss of the amount of a normal protein, and the like.
12333 represents a functional group that is for detection and that has 194566 represents an introduction group that is to be introduced into a nucleic acid oligomer. This guanosine derivative compound can be introduced as a part of a nucleic acid sequence, and the introduced nucleic acid oligomer stabilizes the higher-order structure in a nucleic acid, and enables dynamic detection by 19F NMR.
The present invention prevents, with a simple configuration when guiding livestock into a guiding path one by one, entry of two livestock simultaneously or one after another successively into an entry section of the guiding path. This guided livestock headcount regulating device is provided with: an open/close unit 50 that can be moved between an open position in which the guidance entry section 12 is opened to allow entry of livestock, and a closed position preventing entry. In an initial state permitting entry, the open/close unit is held in the open position. Upon sensing of livestock, the open/close unit is moved in a closing direction toward the closed position, and some of open/close pieces making up the open/close unit permit forward movement of the livestock while coming into contact with the livestock during the movement toward the closed position, whereas the other open/close pieces close a gap between the livestock and the guiding path and prevent entry of other livestock.
B01J 20/08 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising oxides or hydroxides of metals not provided for in group comprising aluminium oxide or hydroxideSolid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising oxides or hydroxides of metals not provided for in group comprising bauxite
B01J 20/12 - Naturally occurring clays or bleaching earth
48.
TESTING METHOD AND AGENT FOR DIAGNOSTIC TOLERANCE TESTING FOR DISTINGUISHING ALDOSTERONE-PRODUCING ADENOMA AND IDIOPATHIC ALDOSTERONISM
Provided are a simple and minimally invasive testing method and an agent for diagnostic tolerance testing for distinguishing aldosterone-producing adenoma and idiopathic aldosteronism. Provided is the agent for diagnostic tolerance testing for distinguishing aldosterone-producing adenoma and idiopathic aldosteronism, which includes adrenocorticotropin as an effective component, and which is characterized in that 90-180 minutes after the tolerance testing agent is administered to a subject, aldosterone in a sample obtained from the subject is measured. Additionally, provided is a testing method for distinguishing aldosterone- producing adenoma and idiopathic aldosteronism.
123344 is any of H, monophosphoric acid, diphosphoric acid, and triphosphoric acid. Thus, a guanosine derivative having a substituent at the 8-position is provided. Use of the guanosine derivative renders nucleic-acid labeling possible.
The present invention pertains to: an immune checkpoint inhibitor containing a CLEC4A function inhibitor such as a CLEC4A function inhibiting antibody, etc.; and an application of the immune checkpoint inhibitor.
A cell labeling agent according to the present invention includes a monosaccharide derivative having a six-membered ring structure metabolized by sialic acid in a sialic acid biosynthesis pathway of a cell. Among groups bonded to carbon atoms constituting the six-membered ring in the monosaccharide derivative, at least one group which does not change even when metabolized by the sialic acid biosynthesis pathway includes a ring structure having a carbon-carbon double bond or triple bond.
C07H 13/12 - Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group —X—C (=X)—X—, or halides thereof, in which X means nitrogen, oxygen, sulfur, selenium, or tellurium, e.g. carbonic acid, carbamic acid
Provided is an ultrasonic vibration machining device with which it is possible to suppress vibration of components due to an ultrasonic transducer, and to carry out machining satisfactorily using ultrasonic vibrations. This ultrasonic vibration machining device is provided with: a housing (10); an ultrasonic transducer (20) which includes a horn portion (21A) to which a tool holder (70) can be detachably attached and a piezoelectric element (23) having a rear end positioned at an ultrasonic vibration node, and which is rotatably supported inside the housing (10); a coupling portion (30) which is rotatably accommodated inside the housing (10) together with the ultrasonic transducer (20); a motor (40) coupled to the coupling portion (30); and a non-contact power feed portion (50) which is fixed to the housing (10) and comprises a primary-side transformer (51) equipped with a primary-side coil (51B) to which high-frequency electric power is supplied from an external power supply, and a secondary-side transformer (52) which is coupled to a rear end of the ultrasonic transducer (20) with a gap maintained to the primary-side transformer (51), and which is equipped with a secondary-side coil (52B) which supplies an induced electromotive force to the piezoelectric element (23).
Provided is a lung adenocarcinoma detection method that is simple and is less invasive. The lung adenocarcinoma detection method of the present invention includes the step of detecting the presence or absence of an abnormal cleavage in kininogen I in a sample collected from a subject in vitro. The abnormal cleavage in kininogen I is, for example, a cleavage that can form at least one cleaved site in a peptide bond in kininogen I and/or a cleavage that causes the deletion of at least one amino acid residue at at least one site in kininogen I. The lung adenocarcinoma detection method according to the present invention includes the step of detecting the presence or amount of a protein having the above-mentioned abnormal cleavage or the loss of the amount of a normal protein, and the like.
The present invention addresses the issue of providing: a method for easily predicting the prognosis for patients with acute dysfunction; and a measurement reagent used in same. A method for providing information for predicting the prognosis for patients with acute dysfunction and including: a step (a) in which the adrenomedullin amount in a specimen from the patient is measured; a step (b) in which the adrenomedullin amount is measured in a specimen that is from the same patient as in step (a) and was collected after the specimen in step (a) was collected; a step (c) in which the difference between the measurement value for (a) and the measurement value for (b) is found; and a step (d) in which, if the difference found in (c) gives a positive value for when the measurement value for (a) is deducted from the measurement value for (b), an associated prediction is made that the prognosis for the patient is poor.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japan)
UNIVERSITY OF MIYAZAKI (Japan)
Konan Gakuen (Japan)
NIPPON SUISAN KAISHA, LTD. (Japan)
Inventor
Sakaguchi, Keishi
Matsuda, Takanori
Kobayashi, Takumi
Ito, Makoto
Nagano, Naoki
Hayashi, Masahiro
Honda, Daisuke
Taoka, Yosuke
Okita, Yuji
Izumida, Hitoshi
Sugimoto, Shinichi
Abstract
A microbial oil is extracted from stramenopile transformed with a gene associated with synthesis of fatty acids, the gene encoding a fatty acid desaturase. The stramenopile belongs to the class Labyrinthulomycete. The microbial oil satisfies one or more of the following requirements: (a) an amount of arachidonic acid is 7% or less based on a total amount of the fatty acid composition; (b) an amount of DPA is 9% or less based on the total amount of the fatty acid composition; (c) an amount of ETA is 0.04% or more based on the total amount of the fatty acid composition; (d) an amount of EPA is 7% or more based on the total amount of the fatty acid composition; and (e) an amount of DHA is 45% or more based on the total amount of the fatty acid composition.
C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats
Provided is a novel long-lasting adrenomedullin derivative that is capable of substantially inhibiting an undesired side reaction while maintaining the pharmacological effect of adrenomedullin. One embodiment of the present invention pertains to a compound represented by formula (I) [wherein: A represents the Fc region of immunoglobulin; B represents a peptide fragment derived from adrenomedullin or a modification thereof having the adrenomedullin activity; and L represents a linking group comprising a peptide having an arbitrary amino acid sequence], a salt thereof or a hydrate of the same. Another embodiment of the present invention pertains to a method for producing a compound represented by formula (I) and a drug comprising the compound as an active ingredient. A-L-B (I)
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
2—B (I) [wherein A is a modifying group comprising one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is linked to the other moieties through a covalent bond of the nitrogen atom of the N-terminal α-amino group of the peptide moiety B to the carbon atom of the methylene group] or a salt thereof, or a hydrate thereof.
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
ANTI-CANCER AGENT, METHOD FOR SCREENING FOR ANTI-CANCER AGENT, KIT FOR DETERMINATION OF EFFICACY ON CANCER, AND METHOD FOR DETERMINING EFFICACY ON CANCER
An anti-cancer agent contains a protein arginine methyl transferase 5 inhibitor, and can be used against cancer in which the expression level of NDRG2 in cancer cells is reduced compared with that in corresponding normal cells. The cancer may be selected from the group consisting of adult T-cell leukemia-lymphoma, osteosarcoma and cervical cancer.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
n-B (I), wherein A is a modifying group selected from the group consisting of a palmitoyl group and a polyethylene glycol group, L is a divalent linking group, n is an integer of 0 or 1, and B is a peptide moiety derived from adrenomedullin or a modified form thereof with adrenomedullin activity, wherein the peptide moiety B is bound to the modifying group A or the linking group L via the N-terminal amino group of the peptide moiety B, or a salt thereof, or a hydrate thereof.
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
[Problem] To provide a practical determination method whereby H type determination can be rapidly and easily performed. [Solution] An Escherichia coli H typing determination method characterized by comprising determining H typing by performing nucleic acid amplification of a polymorphic region of a gene that codes for flagellin constituting flagella of E. coli. Specifically, through the present invention, the H type of E. coli can be genetically determined rapidly and accurately, and it is therefore possible to more appropriately and rapidly prevent infection with or infectious spread of enteropathogenic E. coli including enterohemorrhaghic E. coli in medical or public health/food sanitation settings.
[Problem] To develop a method for detecting the presence/absence of African swine fever virus infection easily and rapidly. [Solution] The present invention provides: an oligonucleotide primer designed on the basis of an optional base sequence, or a base sequence complimentary thereto, the optional base sequence being selected from base sequence Nos. 1503 to 2072 (hereinafter "target nucleic acid") of the base sequence of African swine cholera virus genome (GenBank accession No. AY578689) depicted in SEQ ID NO: 1; and a method for amplifying nucleic acids, such as the LAMP method in which such oligonucleotide primers are used.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
62.
Catalyst particles, carbon-supported catalyst particles and fuel cell catalysts, and methods of manufacturing such catalyst particles and carbon-supported catalyst particles
A catalyst particle is composed of an inner particle and an outermost layer that includes platinum and covers the inner particle. The inner particle includes on at least a surface thereof a first oxide having an oxygen defect.
Provided is a simple and minimally invasive adenocarcinoma detection method. The adenocarcinoma detection method according to the present invention includes a step in which the presence of abnormal cleavage in a specific protein in a sample from a test subject is detected in vitro. Examples of abnormal cleavage include: cleavage that causes one or more breaks in the peptide bonds in the specific protein and cleavage that causes the absence of one or more amino acid residues at one or more sites of the specific protein. This adenocarcinoma detection method has a step for detecting the existence or number of proteins with the described abnormal cleavage, or a reduction in the number of normal proteins.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 14/78 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
64.
Method for prevention or treatment of intractable inflammatory bowel disease
An object of the present invention is to provide methods for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease. The object can be achieved by a method for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease in a patient in need of the prevention or treatment of the inflammatory bowel disease, comprises administering an effective amount of adrenomedullin, a modified product thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, or a salt thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, to the patient.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present invention provides a novel long-acting adrenomedullin derivative with which it is possible to substantially suppress undesirable side effects while maintaining the pharmacological action of adrenomedullin. In one exemplary embodiment, the present invention pertains to a compound represented by formula (I): A-CH2-B (I) [in the formula, A is a modifying group that includes one or more polyethylene glycol groups, and B is a peptide moiety derived from adrenomedullin or a modified form thereof having adrenomedullin activity, where the peptide moiety B is linked to the remainder by covalent bonding of a nitrogen atom of the α amino group of the N-terminal thereof and a carbon atom of a methylene group] or a salt thereof, or a hydrate of these.
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 9/00 - Drugs for disorders of the cardiovascular system
C07K 14/46 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates
This measuring system S is provided with: a slit light irradiation device 2 that emits a plurality of slit laser beams 23a to 23d in the shape of a slit to a tubular body 9; a dot light irradiation device 3 that emits a plurality of dot laser beams in the shape of a dot to the tubular body 9, each dot laser beam having a predetermined positional relationship with each of the slit laser beams 23a to 23d; an imaging device 4 that images a plurality of bright lines L1 to L4 that appear on the surface of the tubular body 9 and a plurality of bright spots D that appear on the surface of the tubular body 9 to generate an image thereof; an identification unit 152 that compares the generated image with a reference image representing predetermined positional relationships between the bright lines L1 to L4 and the bright spots D to identify correspondences between the bright lines L1 to L4 in the generated image and the slit laser beams 23a to 23d; and an acquisition unit 153 that acquires three-dimensional coordinates of the bright lines L1 to L4 on the basis of two-dimensional coordinates of the bright lines L1 to L4 in the generated image and the correspondences identified by the identification unit 152.
G01B 11/25 - Measuring arrangements characterised by the use of optical techniques for measuring contours or curvatures by projecting a pattern, e.g. moiré fringes, on the object
67.
METHOD FOR PRODUCING PROTEIN WITH LIGNIN-DEGRADING ACTIVITY USING THRAUSTOCHYTRID
The present invention addresses the problem of providing a method for producing a protein having lignin-degrading activity or a method for degrading lignin. Provided are a method for producing a protein having lignin-degrading activity and a method for degrading lignin, each method comprising culturing at least one kind of microorganism belonging to thraustochytrids.
It is an object of the present invention to provide an anti-ITGA6/B4 human antibody, which specifically recognizes ITGA6B4 complex expressed on a cell membrane and inhibits the adhesion of the ITGA6B4 complex to laminin, so as to inhibit adhesion of cancer cells to a bone marrow niche, and which is also capable of remarkably enhancing the effects of an anticancer agent on an anticancer agent resistant strain. The present invention provides an antibody against integrin A6B4, wherein the antibody specifically recognizes a human integrin A6B4 complex and inhibits intercellular adhesion.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 39/00 - Medicinal preparations containing antigens or antibodies
The purpose of the present invention is to provide a novel pharmacological composition with which it is possible to suppress the fibrosis of bone marrow associated with myelofibrosis. Examples of the present invention include: (1) a pharmaceutical for suppressing the fibrosis of bone marrow associated with myelofibrosis, the pharmaceutical containing N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide or a pharmacologically acceptable salt or solvate thereof; (2) a pharmacological composition for suppressing the fibrosis of bone marrow associated with myelofibrosis, the pharmacological composition including N-[(2R)-2,3-dihydroxypropoxy]-3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzamide or a pharmacologically acceptable salt or solvate thereof, and a compound having a JAK2-inhibiting effect or a pharmacologically acceptable salt or solvate thereof; and the like.
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/166 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon atom of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
A61P 43/00 - Drugs for specific purposes, not provided for in groups
70.
NOVEL MICROORGANISM BELONGING TO GENUS AURANTIOCHYTRIUM AND METHOD FOR PRODUCING LIQUID FUEL USING SAME
[Problem] Provided are a novel microorganism and the like belonging to the genus Aurantiochytrium and a method for producing liquid fuel using this novel microorganism. In particular, provided are a novel microorganism and the like belonging to the genus Aurantiochytrium having fatty acid production capacity through the introduction of a pentose as a substrate and a method for producing liquid fuel using this novel microorganism. [Solution] A novel microorganism and the like belonging to the genus Aurantiochytrium having fatty acid production capacity through the introduction of a pentose as a substrate and a method for producing liquid fuel having a step for culturing this novel microorganism and accumulating fatty acid in the cells of the novel microorganism, a step for separating the cells of the novel microorganism that have accumulated fatty acid and recovering the fatty acid from the separated cells of the novel microorganism, and a step for oxidizing the recovered fatty acid when the fatty acid recovered includes unsaturated fatty acid.
C12N 1/12 - Unicellular algaeCulture media therefor
C10L 1/02 - Liquid carbonaceous fuels essentially based on components consisting of carbon, hydrogen, and oxygen only
C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats
The present invention provides an antibody, in which the heavy chain first complementarity determining region (VH CDR1), the heavy chain second complementarity determining region (VH CDR2), and the heavy chain third complementarity determining region (VH CDR3) are shown in SEQ ID NOs: 1, 2, and 7, respectively, and the light chain first complementarity determining region (VL CDR1), the light chain second complementarity determining region (VL CDR2), and the light chain third complementarity determining region (VL CDR3) are shown in SEQ ID NOs: 4, 5, and 6, respectively.
C12P 21/04 - Cyclic or bridged peptides or polypeptides, e.g. bacitracin
C12P 21/06 - Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Provided is a novel adrenomedullin derivative capable of acting persistently over a longer period of time than natural adrenomedullin. The present invention pertains to a compound represented by formula (I): A-Ln-B (I) (in the formula, A is a modifying group selected from the group consisting of a palmitoyl group and a polyethylene glycol group, L is a divalent linking group, n is an integer of 0 or 1, and B is a peptide portion derived from adrenomedullin or a modified form thereof having adrenomedullin activity, where the peptide portion B is linked, via the N-terminal amino group thereof, with the linking group L or the modifying group A), or a salt thereof, or a hydrate of these.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
73.
Methods of lowering body temperature by administration of desacyl ghrelin or its derivative
NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (Japan)
DAIICHI SANKYO COMPANY, LIMITED (Japan)
Inventor
Murakami, Noboru
Nakahara, Keiko
Kangawa, Kenji
Abstract
An object of the present invention is to provide a hypothermic agent for an animal, a therapeutic agent for hyperthermia in an animal, etc. The present invention provides a hypothermic agent for an animal, a therapeutic agent for hyperthermia in an animal, etc., the agents etc. comprising desacyl ghrelin or its derivative, or a pharmaceutically acceptable salt thereof as an active ingredient.
The present invention provides a high purity heparin useful to be a pharmaceutical product, cosmetics, research reagent, or the like, and a method for producing the same, more specifically, a heparin which does not substantially contain a nitrous acid degradation-resistant impurity and a method for producing a heparin, comprising mixing an aqueous solution of 5 to 30% by weight of the heparin with ethanol having an amount (volume) 0.2 to 1 times the amount (volume) of the aqueous heparin solution to obtain a colloidal precipitate of heparin.
The purpose of the present invention is to provide an anti-ITGA6/B4 human antibody which is capable of inhibiting the adhesion of cancer cells in a bone marrow niche, and significantly increasing the strength of the effect of an anti-cancer drug against an anticancer-drug-resistant strain, by specifically recognizing the ITGA6B4 complex expressed on a cell membrane, and inhibiting the adhesion of the ITGA6B4 complex and laminin to one another. The present invention provides an antibody to integrin A6B4 which specifically recognizes the human integrin A6B4 complex and inhibits intercellular adhesion.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 13/08 - Drugs for disorders of the urinary system of the prostate
A61P 13/10 - Drugs for disorders of the urinary system of the bladder
A61P 15/00 - Drugs for genital or sexual disordersContraceptives
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
C12N 1/19 - YeastsCulture media therefor modified by introduction of foreign genetic material
C12N 1/21 - BacteriaCulture media therefor modified by introduction of foreign genetic material
C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
Provided are: a novel method for diagnosing adult T cell leukemia, a diagnosis kit therefor; a method for screening a therapeutic agent therefor; and a therapeutic agent. The expression level of SCYL2 gene in cells is detected and the detection result is applied to the method for diagnosing adult T cell leukemia or the method for screening a therapeutic agent therefor. A phosphorylation-inhibiting and/or dephosphorylating agent, which has an effect of inhibiting phosphorylation at least at one of the phosphorylation sites of PTEN protein selected from the group consisting of T382, T383 and S380 and/or an effect of dephosphorylating the same via the regulation of the expression of SCYL2 gene, is prepared.
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
[Problem] To provide a fast and highly accurate method for classifying enterohemorrhagic E. coli O-serogroups that can replace conventional serological O-serogroup classification. [Solution] A pool template that contains a plurality of primer sets and a single template that contains a solo primer set are used to perform nucleic acid amplification of an E-coli O-antigen sample and identification of E-coli O-antigen, said primer sets containing a forward primer and a reverse primer that enable nucleic acid amplification of base sequences of an O-antigen sugar chain synthetase gene (wzy) and an O-antigen sugar chain transporter protein gene (wzx or wzm/wzt) which are present in a gene region that governs O-antigen synthesis in a E. coli chromosome.
NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (Japan)
UNIVERSITY OF MIYAZAKI (Japan)
Inventor
Shibakami Motonari
Tsubouchi Gen
Hayashi Masahiro
Abstract
The purpose of the present invention is to provide: a β-1,3-glucan derivative which is a polymer that has β-1,3-glucan as the main chain, and which has thermal plasticity and excellent moldability; and a method for producing this β-1,3-glucan derivative. Namely, the present invention provides a β-1,3-glucan derivative which is characterized by having a structure that is represented by general formula (1) as the main chain. (In formula (1), R1 represents a hydrogen atom or a -COR2 group; n represents an integer of 1 or more; and R2 represents an aliphatic hydrocarbon group or an aromatic hydrocarbon group. In formula (1), the plurality of R1 groups may be the same as or different from each other, but at least some of the R1 groups are -COR2 groups.)
The present invention addresses the problem of finding a novel composing element of the renin-angiotensin system (RAS) and providing the same as a novel biomarker for a circulatory disease or renal disease. Provided is a novel peptide relating to the renin-angiotensin system, said peptide comprising the amino acid sequence represented by SEQ ID NO:1 or an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:1 by deletion, substitution or addition of one to several amino acids excluding the asparagine residue at the 14th position, characterized in that an N-linked sugar chain is added to the asparagine residue at the 14th position in the aforesaid amino acid sequence. By using this peptide as a biomarker, a renal disease or circulatory disease can be easily diagnosed at an early stage without loading a burden on a subject.
C07K 14/435 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C12Q 1/02 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving viable microorganisms
The present invention provides an antibody wherein a first heavy chain complementarity determining region (VH CDR1), a second heavy chain complementarity determining region (VH CDR2), and a third heavy chain complementarity determining region (VH CDR3) are SEQ ID NOs: 1, 2 and 7, respectively, and a first light chain complementarity determining region (VL CDR1), a second light chain complementarity determining region (VL CDR2), and a third light chain complementarity determining region (VL CDR3) are SEQ ID NOs: 4, 5 and 6, respectively.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
An object of present invention is to provide a complete human anti-human TfR antibody, which specifically recognizes human TfR, inhibits the survival or growth of cancer cells that highly express TfR, and has no immunogenicity to humans. The present invention provides an antibody which specifically reacts with human TfR, wherein the antibody comprises any one of the amino acid sequences shown in SEQ ID NOS: 1-3, 7-9, 13-15, 19-21, 25-27, 31-33, 37-39, 43-45, 49-51, 55-57, 61-63, 67-69, 73-75, 79-81, 85-87, 91-93, 97-99, 103-105, 109-111, and 115-117, as each of a heavy chain first complementarity determining region (VH CDR1), a heavy chain second complementarity determining region (VH CDR2), and a heavy chain third complementarity determining region (VH CDR3).
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japan)
UNIVERISTY OF MIYAZAKI (Japan)
KONAN GAKUEN (Japan)
NIPPON SUISAN KAISHA, LTD. (Japan)
Inventor
Sakaguchi, Keishi
Hamaguchi, Rie
Matsuda, Takanori
Ito, Makoto
Nagano, Naoki
Hayashi, Masahiro
Honda, Daisuke
Okita, Yuji
Sugimoto, Shinichi
Abstract
Parietichytrium sp. and the gene to be disrupted or of which the expression is to be inhibited is a gene associated with the biosynthesis of a fatty acid.
C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats
C12N 15/52 - Genes encoding for enzymes or proenzymes
83.
Method for prevention or treatment of intractable inflammatory bowel disease
An object of the present invention is to provide methods for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease. The object can be achieved by a method for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease in a patient in need of the prevention or treatment of the inflammatory bowel disease, comprises administering an effective amount of adrenomedullin, a modified product thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, or a salt thereof having an activity of suppressing steroid-resistant or steroid-dependent inflammation, to the patient.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
[Problem] To provide a means whereby diabetic arteriosclerosis can be diagnosed in distinction from non-diabetic arteriosclerosis. [Solution] According to one embodiment of the present invention, a method for examining arteriosclerosis is provided. This examination method is characterized by comprising a step for measuring the quantity of a metabolite in a test sample that is collected from a test subject, and a step for examining diabetic arteriosclerosis or non-diabetic arteriosclerosis in the test subject using the measured value as an index.
G01N 27/62 - Investigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating the ionisation of gases, e.g. aerosolsInvestigating or analysing materials by the use of electric, electrochemical, or magnetic means by investigating electric discharges, e.g. emission of cathode
G01N 33/483 - Physical analysis of biological material
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
G01N 33/70 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving creatine or creatinine
85.
High purity heparin and production method therefor
The present invention provides a high purity heparin useful to be a pharmaceutical product, cosmetics, research reagent, or the like, and a method for producing the same, more specifically, a heparin which does not substantially contain a nitrous acid degradation-resistant impurity and a method for producing a heparin, comprising mixing an aqueous solution of 5 to 30% by weight of the heparin with ethanol having an amount (volume) 0.2 to 1 times the amount (volume) of the aqueous heparin solution to obtain a colloidal precipitate of heparin.
NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER (Japan)
DAIICHI SANKYO COMPANY, LIMITED (Japan)
Inventor
Murakami, Noboru
Nakahara, Keiko
Kangawa, Kenji
Hayashi, Yujiro
Abstract
An object of the present invention is to provide a therapeutic agent for accelerating recovery to accelerate a return to normal physical conditions by administering to an animal not in good health and under medical treatment, a treatment method, and the like. There is provided a therapeutic agent for accelerating recovery for animal use to accelerate the improvement of a physical condition of an animal under medical treatment which has a decreased activity (vigor) and is exhausted, which contains ghrelin or a derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient and improves one or more of evaluation parameters consisting of activity (vigor), blood cell test values, biochemical test values, body temperature, the degree of anger or anxiety, and respiratory rate.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japan)
NATIONAL UNIVERSITY CORPORATION SHIZUOKA UNIVERSITY (Japan)
Inventor
Kamei Ichiro
Meguro Sadatoshi
Kondo Ryuichiro
Mori Toshio
Hirai Hirofumi
Abstract
The purpose of the present invention is to provide a means for producing ethanol from a carbon source derived from a plant biomass resource or the like in a simple manner and with high efficiency. The present invention relates to a method for producing ethanol, comprising a step of culturing a basidiomycete belonging to the genus Phlebia together with a carbon source to produce ethanol. Cellulose, hemicellulose, glucose, xylose or the like or a plant biomass resource containing any one of these component can be used as the carbon source.
[Problem] To provide: a means for preventing/treating cancer by controlling the expression/function of a target cell that is different from those employed in conventional means, as a novel means to be employed in a molecular targeting therapy for cancer; a means for screening for a substance having a prophylactic/therapeutic activity on cancer, which utilizes the target molecule; and a simple and rapid means for testing cancer utilizing the detection of the target molecule. [Solution] According to one embodiment of the present invention, a cell proliferation inhibitor and a cell adhesion inhibitor for cancer cells are provided, each of which comprises an antibody against a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 2 or a partial peptide of the protein. According to another embodiment of the present invention, a cell adhesion inhibitor for cancer cells is provided, which comprises an antisense polynucleotide comprising a nucleotide sequence complementary to or substantially complementary to a nucleotide sequence for a polynucleotide that encodes a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 2 or a part of the nucleotide sequence. According to a further embodiment of the present invention, a cell adhesion inhibitor for cancer cells is provided, which comprises a substance capable of inhibiting the expression and/or activity of a protein that comprises the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 2. According to a still another embodiment of the present invention, a method for testing cancer is provided, which comprises a step of detecting a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 2 or a partial peptide of the protein, or detecting a polynucleotide that encodes a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 2. Further provided is a test kit for use in the method, which comprises an antibody against a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 2 or a partial peptide of the protein, or comprises a primer or probe for detecting a polynucleotide that encodes a protein having the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 2.
The purpose of the present invention is to provide a complete human anti-human TfR antibody that specifically recognises human TfR, inhibits the survival and multiplication of cancer cells in which TfR is overexpressed, and exhibits no immunogenicity in humans. The antibody that specifically responds to human TfR respectively contains as the heavy chain first complementarity determining region (VHCDR1), the heavy chain second complementarity determining region (VHCDR2), and the heavy chain third complementarity determining region (VHCDR3), amino acid sequences represented by any of the following SEQ ID NOs.: 1-3, 7-9, 13-15, 19-21, 25-27, 31-33, 37-39, 43-45, 49-51, 55-57, 61-63, 67-69, 73-75, 79-81, 85-87, 91-93, 97-99, 103-105, 109-111, 115-117.
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 35/02 - Antineoplastic agents specific for leukemia
National Cerebral and Cardiovascular Center (Japan)
DAIICHI SANKYO COMPANY, LIMITED (Japan)
Inventor
Murakami, Noboru
Nakahara, Keiko
Kangawa, Kenji
Hayashi, Yujiro
Abstract
The invention addresses the problem of providing a hypothermic agent for animals, a therapeutic agent for hyperthermia for animals or the like. According to the invention, a hypothermic agent for animals, a therapeutic agent for hyperthermia for animals or the like, each containing desacyl ghrelin or a derivative thereof or a pharmaceutically acceptable salt thereof as an active ingredient are provided.
The present invention provides a porphyrin derivative having improved water solubility, desirably having both water solubility and lipophilicity. Specifically, the present invention provides a water-soluble porphyrin consisting of a tetraphenylporphyrin derivative represented by Formula (1):
−.
C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
C07F 9/6584 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
C09B 69/00 - Dyes not provided for by a single group of this subclass
92.
HUMIDITY AND HEAT RESISTANT FILM, MANUFACTURING METHOD FOR SAME, DEVICE AND SOLAR BATTERY
Provided is a humidity and heat resistant film comprising a translucent conducting film containing ZnO and in which the loss of conductance in high temperature and high humidity environments is controlled. This humidity and heat resistant film has a humidity and heat resistance of Ra/Rb 0.9 to 5.0, Ra/Rb being the ratio of the sheet resistance value after 1000 hours in an environment of 85ºC with a relative humidity of 85% (Ra) and the sheet resistance value immediately prior to exposure to such environment (Rb), and the film is a translucent conductive film containing indium doped zinc oxide with an indium doping level of 1.5mol% or greater in relation to the zinc oxide.
The purpose of the present invention is to provide a method for preventing a steroid-resistant or steroid-dependent inflammatory bowel disease and a method for treating the disease. The method for preventing or treating a steroid-resistant or steroid-dependent inflammatory bowel disease comprises administering, to a patient having a need for the prevention or treatment of said inflammatory bowel disease, an effective dose of adrenomedullin, a modification thereof that has an activity of inhibiting steroid-resistant or steroid-dependent inflammation, or a salt of the same that has an activity of inhibiting steroid-resistant or steroid-dependent inflammation.
The invention provides a prophylactic or therapeutic agent for diabetes, cachexia, etc. comprising a peptide, which comprises an amino acid sequence represented by SEQ ID NO: 8 or a partial sequence thereof and also comprises an amino acid sequence containing an amino acid sequence represented by SEQ ID NO: 1, or a pharmacologically acceptable salt thereof as an active ingredient. Further, the invention provides a screening method for a substance which promotes or suppresses the activity of the peptide or an agonist or antagonist for a receptor for the peptide using the peptide or a salt thereof.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
95.
CATALYST PARTICLES, CARBON-SUPPORTED CATALYST PARTICLES AND FUEL CELL CATALYSTS, AND METHODS OF MANUFACTURING SUCH CATALYST PARTICLES AND CARBON-SUPPORTED CATALYST PARTICLES
A catalyst particle is composed of an inner particle and an outermost layer that includes platinum and covers the inner particle. The inner particle includes on at least a surface thereof a first oxide having an oxygen defect.
KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION (Japan)
UNIVERSITY OF MIYAZAKI (Japan)
KONAN GAKUEN (Japan)
NIPPON SUISAN KAISHA, LTD. (Japan)
Inventor
Sakaguchi, Keishi
Hamaguchi, Rie
Matsuda, Takanori
Ito, Makoto
Nagano, Naoki
Hayashi, Masahiro
Honda, Daisuke
Okita, Yuji
Sugimoto, Shinichi
Abstract
[Problem] To provide a transformation method for producing a stramenopile organism having an improved unsaturated fatty acid production capability by disrupting a gene of the stramenopile organism or inhibiting the expression of the gene in a genetically engineering manner. [Solution] A method for transforming a stramenopile organism, which comprises disrupting a gene of the stramenopile organism or inhibiting the expression of the gene in a genetically engineering manner, and which is characterized in that the stramenopile organism is selected from Thraustochytrium aureum, Parietichytrium sarkarianum, Thraustochytrium roseum and Parietichytrium sp. and the gene to be disrupted or of which the expression is to be inhibited is a gene associated with the biosynthesis of a fatty acid.
C12N 1/15 - Fungi Culture media therefor modified by introduction of foreign genetic material
C12P 7/64 - FatsFatty oilsEster-type waxesHigher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl groupOxidised oils or fats
The present invention provides a high purity heparin useful as a medicine, a cosmetic, a research reagent and the like, and a production method therefor, in more detail, a method for producing heparin, the method comprising mixing a heparin without substantially containing nitrous acid degradation-resistant impurities with 0.2 to 1 time (volume) the amount of ethanol to 5 to 30 wt% of heparin solution, and obtaining a colloidal precipitate of heparin.
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
The purpose of the present invention is to provide a composition that has the effect of suppressing matrix-metalloproteinase activity. Specifically, the present invention pertains to a composition which suppresses matrix-metalloproteinase activity and contains, as an active ingredient, a glucose-metabolism inhibitor.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
The present invention provides a peptide that is an antagonist for SP and suppresses pain, inflammation, and itching. Furthermore, the present invention provides a method for searching for analgesic, anti-inflammatory, and anti-itch medication that use a receptor specific to HK-1, said receptor being G protein-coupled receptor (GPR) 83.
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
An object of the present invention is to provide a method for controlling microorganisms in food materials, by which bacterial groups that cause deterioration of the quality of food materials such as poultry and pathogenic microorganisms that cause food poisoning can be efficiently controlled. Specifically, the present invention relates to a method for controlling microorganisms in food materials, comprising a step of subjecting a food material immersed in a sterilizing solution to repeated treatment with negative pressure and ordinary pressure and/or a step of subjecting the food material immersed in the sterilizing solution to resonant ultrasonication.
patents
